Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6856486 | 0.84 | CA12 (0.54) | SMN1; SMN2ALDH1A1ABCB1KDM4EABCG2 | |
| Hydrochloric Acid SCHEMBL17318418 | 0.83 | SMN1; SMN2 (0.50) | IDO1SMN1; SMN2ALDH1A1ABCB1KDM4E | |
| SCHEMBL3306584 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2ALDH1A1ABCB1KDM4EABCG2 | |
| Hydrochloric Acid SCHEMBL5485820 | 0.82 | CA12 (0.51) | IDO1SMN1; SMN2ALDH1A1ABCB1KDM4E | |
| SCHEMBL775238 | 0.81 | AOC3 (0.53) | SMN1; SMN2ALDH1A1KDM4EPOLBGAA | |
| SCHEMBL464374 | 0.81 | CA12 (0.54) | SMN1; SMN2ALDH1A1ABCB1KDM4EABCG2 | |
| SCHEMBL43208 | 0.80 | IDO1 (0.61) | IDO1SMN1; SMN2ALDH1A1CA12CA1 | |
| SCHEMBL11567490 | 0.80 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1ABCB1KDM4EABCG2 | |
| Hydrochloric Acid SCHEMBL31658961 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1KDM4ECA12CA1 | |
| SCHEMBL95872 | 0.79 | CA12 (0.53) | SMN1; SMN2ALDH1A1ABCB1KDM4EABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511730-B8 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2009-04-08 | — | — | EP | claimed |
| EP-1865963-A2 | TRIAZADIBENZOAZULENE COMPOUNDS USEFUL FOR THE TREATMENT AND PREVENTION OF PAIN AND SCREENING METHODS THEREFOR | Acadia Pharmaceuticals Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| US-20060217370-A1 | Compounds useful for the treatment and prevention of pain and screening methods therefor | ACADIA PHARMACEUTICALS INC. | 2006-09-28 | — | — | US | claimed |
| WO-2006089286-A2 | TRIAZADIBENZOAZULENE COMPOUNDS USEFUL FOR THE TREATMENT AND PREVENTION OF PAIN AND SCREENING METHODS THEREFOR COMPOUNDS USEFUL FOR THE TREATMENT AND PREVENTION OF PAIN AND SCREENING METHODS THEREFOR | ACADIA PHARMACEUTICALS INC. (US) | 2006-08-24 | — | — | WO | claimed |
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | FLOERSHEIMER ANDREAS | 2006-06-15 | — | — | US | claimed |
| CN-1656073-A | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2005-08-17 | — | — | CN | claimed |
| EP-1511730-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2005-03-09 | — | — | EP | claimed |
| WO-2003099771-A2 | DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2003-12-04 | — | — | WO | claimed |
| EP-1155001-A4 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | LION BIOSCIENCE AG (DE) | 2003-05-28 | — | — | EP | claimed |
| US-6515122-B1 | The invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing tetracyclic benzimidazole derivative compounds. | LION BIOSCIENCE AG (DE) | 2003-02-04 | — | — | US | claimed |
| EP-1155001-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 2001-11-21 | — | — | EP | claimed |
| WO-2001023392-A1 | TETRACYCLIC BENZIMIDAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-04-05 | — | — | WO | claimed |
| WO-2000050406-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | LION BIOSCIENCE AG (DE) | 2000-08-31 | — | — | WO | claimed |
| EP-0635508-B1 | TETRAHYDROPYRIDINE DERIVATIVE HAVING SUBSTITUENTS ON THREE RINGS | ASAHI CHEMICAL IND (JP) | 1999-10-06 | — | — | EP | claimed |
| EP-0863877-A4 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INST (US) | 1999-07-21 | — | — | EP | claimed |
| US-5874443-A | BIOSYNTHESIS | TREGA BIOSCIENCES, INC. (US) | 1999-02-23 | — | — | US | claimed |
| EP-0863877-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1998-09-16 | — | — | EP | claimed |
| WO-1997016428-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1997-05-09 | — | — | WO | claimed |
| US-5621103-A | 3-(SUBSTITUTED METHYLAMINOCARBONYL)-1,2,3,4-TETRAHYDRO-(1)BENZOTHIENO(2,3-C) PYRIDINES; ANXIOLYTIC AGENTS; LEARNING ENHANCEMENT | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1997-04-15 | — | — | US | claimed |
| EP-0635508-A1 | TETRAHYDROPYRIDINE DERIVATIVE HAVING SUBSTITUENTS ON THREE RINGS | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1995-01-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128734-A1 | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | UCK2, PRKDC, PRKACA | IDO1 3722/4885SMN1; SMN2 2710/4885ALDH1A1 3040/4885 |
| US-20060217370-A1 | Compounds useful for the treatment and prevention of pain and screening methods therefor | ACHE, OPRL1, OPRK1 | IDO1 3760/4885SMN1; SMN2 1227/4885ALDH1A1 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.